Keytruda combination therapy for liver cancer approved by FDA for breakthrough therapy

Over the past 10 years, the incidence and mortality of HCC has been steadily increasing, while China has one of the highest incidenceof liver cancers in the world, accounting for 50% of new cases of liver cancer worldwideHCC accounts for 90% of the total number of liver cancers, and the stage of development of the disease at the time of diagnosis has a great impact on the treatment methods and the patient's prognosisPotential cures such as liver removal or liver transplantation can only be used in early HCC patientsThe prognosis of HCC patients who could not be removed was poor, with a median survival period of not more than one yearUnfortunately, 70% of patients are unable to receive a cut or transplant at the time of diagnosis, and their treatment options are very limitedPD-1 inhibitor Keytruda has been approved by the FDA for the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, liver cell carcinoma (second-line treatment for patients with liver cell cancer previously treated with the targeted drug sorafenib), kidney cancer and more than 10 kinds of cancer indicationsIn July 2018, Keytruda (Corrida, PaboliZumab) was approved in China to treat patients with non-removable or metastatic melanoma who failed first-line treatment, becoming the first PD-1 inhibitor drug in China to treat advanced melanomaIn March 2019, Keytruda was approved in China in conjunction with Permequei, Cisplatin for first-line treatment of eGFR and ALK-negative metastatic non-squamous non-small cell lung cancerLenvima, an oral tyrosine kinase inhibitor, received FDA approval in June 2018 to treat patients with hepatocellular cancer who cannot be removed, becoming the first new systemic treatment for liver cancer in a decadeOn September 5, 2018, China's State Drug Administration approved Lenvima (LeWeima, methicillatini) single drug treatment for non-removable liver cancer patients who had not previously been systematically treateda partnership between Mercado and Eision in March 2018 to expand Lenvima's indications and explore the effectiveness of its combination with Keytruda in treating a range of cancer typesUnder the agreement, the two companies will jointly launch new clinical trials to assess the effectiveness of a combination of Lenvima and Keytruda in the treatment of six different cancers ( endometrial cancer , non-small cell lung cancer , hepatocellular carcinoma , head and neck cancer , bladder cancer and melanoma )References:.®®Retrieved 2019-07-23, fromOriginal Title: Express, First-line Treatment of Liver Cancer, Keytruda Combination Therapy Recognized by FDA Breakthrough Therapy